Poseida secures cell therapies deal worth up to $600m with Xyphos
The partnership will combine Poseida Therapeutics’ allogeneic CAR-T platform with Xyphos Biosciences’ ACCEL technology to develop convertibleCAR programmes…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
03 May 24
The partnership will combine Poseida Therapeutics’ allogeneic CAR-T platform with Xyphos Biosciences’ ACCEL technology to develop convertibleCAR programmes…
03 May 24
BridgeBio Oncology Therapeutics will advance the development of its oncology portfolio of three initial cancer treatment programmes, which…
03 May 24
Bruker Corporation (Nasdaq: BRKR) is pleased to announce the closing of its acquisition of ELITechGroup (“ELITech”) for €870…
03 May 24
The latest Goli Gummy is made with matcha powder and Cognizin to help support focus and attention
03 May 24
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the availability of QCI Secondary Analysis, a cloud-based software-as-a-services…
02 May 24
Poseida will combine its unique allogeneic CAR-T platform with Xyphos' ACCELTM technology to create one Poseida-developed CAR-T construct,…
02 May 24
The high-concentration, citrate-free formulation of Cyltezo injection is now authorised in the US to treat multiple chronic inflammatory…
02 May 24
The CardiAMP Cell Therapy increased the exercise tolerance by 107-second and reduced angina episodes by 82% at the…
02 May 24
As per the partnership, Nasdaq-listed Editas Medicine and Bristol Myers Squibb will research, develop, and market T cell…
02 May 24
A new study published in Diagnostic Microbiology & Infectious Disease shows that Copan’s Colibrí™ instrument accurately automates sample preparation…